Still, the complex nature (e.g., multiple anticancer modalities) of the system and potentially conflicting functions of some therapeutic components (e.g., GM-CSF transgene) necessitate more comprehensive immune profiling of the combined regimen in the future to ascertain how this system function in different tumor types. The gene discussed is CSF2; the disease is neoplasm.